These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9208285)

  • 41. High fluid intake or pharmacological therapy in recurrent stone former patients?
    Aroldi A; Graziani G; Passerini P; Castelnovo C; Mandressi A; Trinchieri A; Colussi G; Ponticelli C
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():743-6. PubMed ID: 3991571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Value of the urinary stone promoters/inhibitors ratios in the estimation of the risk of urolithiasis.
    Batinić D; Milosević D; Blau N; Konjevoda P; Stambuk N; Barbarić V; Subat-Dezulović M; Votava-Raić A; Nizić L; Vrljicak K
    J Chem Inf Comput Sci; 2000; 40(3):607-10. PubMed ID: 10850766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diurnal oscillations of calcium ions, total calcium and oxalates in the urine of patients with calcium oxalate urolithiasis and normal persons].
    Januzović N
    Med Pregl; 1981; 34(11-12):507-12. PubMed ID: 7200567
    [No Abstract]   [Full Text] [Related]  

  • 44. [Idiopathic hypercalciuria].
    Tsujimura H; Hiraishi K
    Nihon Hinyokika Gakkai Zasshi; 1983 Mar; 74(3):368-78. PubMed ID: 6632446
    [No Abstract]   [Full Text] [Related]  

  • 45. Urinary ionic calcium and binding sites in normocalciuric idiopathic calcium urolithiasis.
    Jacobson AL; Singhal PC; Mandin H; Hyne JB
    Invest Urol; 1979 Nov; 17(3):218-22. PubMed ID: 500320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Modification of the risk of urolithiasis by changes in magnesium and calcium concentrations in the urine as affected by stress conditions].
    Brundig P; Börner RH; Schulz E; Pirlich W
    Z Urol Nephrol; 1985 May; 78(5):245-51. PubMed ID: 4036378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment.
    Hallson PC; Rose GA
    Br J Urol; 1976; 48(7):515-24. PubMed ID: 13904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronopharmacological studies on potassium citrate treatment of oxalocalcic urolithiasis.
    Grases F; Conte A; March JG; García-Ferragut L; Villalonga N
    Int Urol Nephrol; 1997; 29(3):263-73. PubMed ID: 9285296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of urinary supersaturation in the evaluation of children with urolithiasis.
    Lande MB; Varade W; Erkan E; Niederbracht Y; Schwartz GJ
    Pediatr Nephrol; 2005 Apr; 20(4):491-4. PubMed ID: 15717161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The definition of the mechanism of hypercalciuria is necessary for the treatment of recurrent stone formers.
    Pak CY; Nicar M; Northcutt C
    Contrib Nephrol; 1982; 33():136-51. PubMed ID: 6749417
    [No Abstract]   [Full Text] [Related]  

  • 51. [Calcium-dependent calcium oxalate lithiasis (type IIa). The importance of urinary citrate and the calcium/citrate ratio].
    Boess G; Parent X
    Presse Med; 1999 Apr; 28(15):784-6. PubMed ID: 10325933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Symposium on renal lithiasis. Renal lithiasis in review.
    Finlayson B
    Urol Clin North Am; 1974 Jun; 1(2):181-212. PubMed ID: 4372765
    [No Abstract]   [Full Text] [Related]  

  • 53. [Therapeutic measures in recurrent calcium oxalate nephrolithiasis].
    Tschöpe W; Schmidt-Gayk H; Ritz E
    Schweiz Rundsch Med Prax; 1978 Sep; 67(38):1385-8. PubMed ID: 211499
    [No Abstract]   [Full Text] [Related]  

  • 54. Sodium is neither a risk nor a protective factor in urolithiasis?
    Singh PP; Pendse AK; Hada P; Nagori PC; Rathore V; Dashora PK
    Urol Res; 1987; 15(2):105-8. PubMed ID: 3590427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medical treatment to prevent recurrent calcium urolithiasis. A guide to critical appraisal.
    Churchill DN
    Miner Electrolyte Metab; 1987; 13(4):294-304. PubMed ID: 3627054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapy of nephrolithiasis].
    Tschöpe W; Ritz E
    Dtsch Med Wochenschr; 1985 Mar; 110(10):385-8. PubMed ID: 3971867
    [No Abstract]   [Full Text] [Related]  

  • 57. Thiazide does not affect urine oxalate excretion.
    Parks JH; Coe FL
    J Urol; 2003 Aug; 170(2 Pt 1):393-6. PubMed ID: 12853783
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Metabolic investigation of calcium oxalate urinary lithiasis. Indicators of lithogenic risk: modalities, applications and perspectives].
    Robert M
    Prog Urol; 1996 Feb; 6(1):44-51. PubMed ID: 8624527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Supersaturated urine.
    Lancet; 1979 Jun; 1(8128):1219-20. PubMed ID: 87681
    [No Abstract]   [Full Text] [Related]  

  • 60. Calcium restriction, thiazide, citrate, and allopurinol in calcium oxalate nephrolithiasis.
    Coe FL
    Acta Urol Belg; 1994 Jun; 62(2):25-9. PubMed ID: 8037000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.